|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 Grifols SA 20-F 12/31/23 228:143M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 13.68M
Non-Canadian Issuer
2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 144K
4: EX-2.14 Plan of Acquisition, Reorganization, Arrangement, HTML 78K
Liquidation or Succession
5: EX-2.17 Plan of Acquisition, Reorganization, Arrangement, HTML 82K
Liquidation or Succession
3: EX-2.9 Plan of Acquisition, Reorganization, Arrangement, HTML 78K
Liquidation or Succession
6: EX-4.6 Instrument Defining the Rights of Security Holders HTML 935K
10: EX-13.1 Annual or Quarterly Report to Security Holders HTML 60K
12: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 79K
Awarded Compensation
7: EX-11.1 Statement re: the Computation of Earnings Per HTML 134K
Share
8: EX-12.1 Statement re: the Computation of Ratios HTML 63K
9: EX-12.2 Statement re: the Computation of Ratios HTML 63K
11: EX-15.1 Letter re: Unaudited Interim Financial Info HTML 58K
18: R1 Document and Entity Information HTML 140K
19: R2 Consolidated Balance Sheet HTML 199K
20: R3 Consolidated Statements of Profit and Loss HTML 121K
21: R4 Consolidated Statements of Comprehensive Income HTML 93K
22: R5 Consolidated Statements of Cash Flows HTML 167K
23: R6 Statement of Changes in Consolidated Equity HTML 118K
24: R7 Nature, Principal Activities and Subsidiaries HTML 63K
25: R8 Basis of Presentation HTML 176K
26: R9 Business Combinations and Divestments HTML 422K
27: R10 Significant Accounting Policies HTML 175K
28: R11 Segment Reporting HTML 94K
29: R12 Goodwill HTML 375K
30: R13 Other Intangible Assets HTML 133K
31: R14 Leases HTML 131K
32: R15 Property, Plant and Equipment HTML 69K
33: R16 Equity-Accounted Investees and Joint Business HTML 415K
34: R17 Financial Assets HTML 130K
35: R18 Non-current assets held for sale HTML 67K
36: R19 Inventories HTML 84K
37: R20 Contract assets HTML 69K
38: R21 Trade and Other Receivables HTML 90K
39: R22 Cash and Cash Equivalents HTML 69K
40: R23 Equity HTML 126K
41: R24 Earnings Per Share HTML 108K
42: R25 Non-Controlling Interests HTML 419K
43: R26 Provisions HTML 264K
44: R27 Financial Liabilities HTML 549K
45: R28 Trade and Other Payables HTML 75K
46: R29 Other Current Liabilities HTML 71K
47: R30 Net Revenues HTML 219K
48: R31 Personnel Expenses HTML 87K
49: R32 Expenses by Nature HTML 126K
50: R33 Finance Result HTML 93K
51: R34 Taxation HTML 173K
52: R35 Other Commitments with Third Parties and Other HTML 124K
Contingent Liabilities
53: R36 Financial Instruments HTML 869K
54: R37 Balances and Transactions with Related Parties HTML 245K
55: R38 Subsequent events HTML 98K
56: R39 Appendix I HTML 1.44M
57: R40 Appendix II HTML 594K
58: R41 Appendix III HTML 185K
59: R42 Appendix IV HTML 192K
60: R43 Appendix V HTML 240K
61: R44 Significant Accounting Policies (Policies) HTML 215K
62: R45 Basis of Presentation (Tables) HTML 138K
63: R46 Business Combinations and Divestments (Tables) HTML 401K
64: R47 Significant Accounting Policies (Tables) HTML 76K
65: R48 Segment Reporting (Tables) HTML 80K
66: R49 Goodwill (Tables) HTML 356K
67: R50 Other Intangible Assets (Tables) HTML 123K
68: R51 Leases (Tables) HTML 132K
69: R52 Equity-Accounted Investees (Tables) HTML 388K
70: R53 Financial Assets (Tables) HTML 131K
71: R54 Inventories (Tables) HTML 85K
72: R55 Contract assets (Tables) HTML 67K
73: R56 Trade and Other Receivables (Tables) HTML 85K
74: R57 Cash and Cash Equivalents (Tables) HTML 68K
75: R58 Equity (Tables) HTML 111K
76: R59 Earnings Per Share (Tables) HTML 105K
77: R60 Non-Controlling Interests (Tables) HTML 398K
78: R61 Provisions (Tables) HTML 270K
79: R62 Financial Liabilities (Tables) HTML 537K
80: R63 Trade and Other Payables (Tables) HTML 73K
81: R64 Other Current Liabilities (Tables) HTML 70K
82: R65 Net Revenues (Tables) HTML 222K
83: R66 Personnel Expenses (Tables) HTML 87K
84: R67 Expenses by Nature (Tables) HTML 128K
85: R68 Finance Result (Tables) HTML 91K
86: R69 Taxation (Tables) HTML 160K
87: R70 Other Commitments with Third Parties and Other HTML 95K
Contingent Liabilities (Tables)
88: R71 Financial Instruments (Tables) HTML 852K
89: R72 Balances and Transactions with Related Parties HTML 237K
(Tables)
90: R73 Subsequent events (Tables) HTML 91K
91: R74 Appendix I (Tables) HTML 1.43M
92: R75 Appendix II (Tables) HTML 594K
93: R76 Appendix III (Tables) HTML 182K
94: R77 Appendix IV (Tables) HTML 188K
95: R78 Appendix V (Tables) HTML 238K
96: R79 Nature, Principal Activities and Subsidiaries HTML 68K
(Details)
97: R80 Basis of Presentation (Details) HTML 202K
98: R81 Business Combinations and Divestments - Cost, FV HTML 468K
of Assets, Goodwill and Other (Details)
99: R82 Business Combinations and Divestments - Amounts HTML 239K
Determined at Acquisition (Details)
100: R83 Significant Accounting Policies - Intangible HTML 72K
assets (Details)
101: R84 Significant Accounting Policies - Property, plant HTML 71K
and equipment (Details)
102: R85 Significant Accounting Policies - Revenue HTML 65K
recognition (Details)
103: R86 Segment Reporting - Additional Information HTML 65K
(Details)
104: R87 Segment Reporting - Net Sales by Groups of HTML 75K
Products (Details)
105: R88 Segment Reporting - Main Customer (Details) HTML 70K
106: R89 Goodwill - Details of and movement in goodwill HTML 136K
(Details)
107: R90 Goodwill - Impairment testing (Details) HTML 104K
108: R91 Goodwill - Schedule of reasonable possible changes HTML 79K
(Details)
109: R92 Other Intangible Assets - Currently marketed HTML 120K
products acquired from Talecris and Progenika
(Details)
110: R93 Other Intangible Assets - Others (Details) HTML 79K
111: R94 Leases - Details of leases in the consolidated HTML 77K
balance sheet (Details)
112: R95 Leases - Schedule of undiscounted future payments HTML 74K
classified on a maturity basis (Details)
113: R96 Leases - Maturity of lease liabilities detail HTML 60K
(Details)
114: R97 Leases - Amounts recognized in the consolidated HTML 82K
statement of profit and loss (Details)
115: R98 Property, Plant and Equipment - Activity (Details) HTML 62K
116: R99 Property, Plant and Equipment - Self Constructed HTML 63K
PP&E and Commitments (Details)
117: R100 Property, Plant and Equipment - Purchase HTML 60K
Commitments (Details)
118: R101 Property, Plant and Equipment -Fixed assets under HTML 63K
construction (Details)
119: R102 Property, Plant and Equipment - Impairment Testing HTML 61K
(Details)
120: R103 Property, Plant and Equipment - Transfers HTML 60K
(Details)
121: R104 Equity-Accounted Investees - Ownership and HTML 96K
carrying amount (Details)
122: R105 Equity-Accounted Investees - Movement in the HTML 119K
investments in equity-accounted investees
(Details)
123: R106 Equity-Accounted Investees - Grifols Egypt for HTML 138K
Plasma Derivatives (S.A.E.) and Shanghai RAAS
Blood Products Co. Ltd (Details)
124: R107 Equity-Accounted Investees - Access Biologicals HTML 75K
LLC (Details)
125: R108 Equity-Accounted Investees - BioDarou P.J.S. Co. HTML 68K
(Details)
126: R109 Equity-Accounted Investees - Albajuna HTML 80K
Therapeutics, S.L. (Details)
127: R110 Equity-Accounted Investees - Medcom Advance,S.A. HTML 64K
(Details)
128: R111 Equity-Accounted Investees - Mecwins, S.A. HTML 66K
(Details)
129: R112 Equity-Accounted Investees - GigaGen Inc (Details) HTML 78K
130: R113 Equity-Accounted Investees - Most recent financial HTML 102K
statements available of the main equity-accounted
investments of Grifols (Details)
131: R114 Equity-Accounted Investees - Joint Arrangement HTML 97K
(Details)
132: R115 Equity-Accounted Investees - Estimated payments on HTML 77K
plasma centers (Details)
133: R116 Equity-Accounted Investees - Breakdown of balances HTML 100K
in joint arrangement (Details)
134: R117 Financial Assets - Non current financial assets HTML 76K
(Details)
135: R118 Financial Assets - Other current financial assets HTML 69K
(Details)
136: R119 Financial Assets - Other non-current and current HTML 73K
financial assets (Details)
137: R120 Financial Assets - Non-current and current loans HTML 63K
(Details)
138: R121 Non-current assets held for sale (Details) HTML 101K
139: R122 Inventories (Details) HTML 74K
140: R123 Inventories - Movement in inventory provisions HTML 70K
(Details)
141: R124 Contract assets (Details) HTML 74K
142: R125 Trade and Other Receivables - Summary (Details) HTML 84K
143: R126 Trade and Other Receivables - Other Receivables HTML 82K
(Details)
144: R127 Cash and Cash Equivalents (Details) HTML 65K
145: R128 Equity - Share Capital - General Information HTML 68K
(Details)
146: R129 Equity - Share Capital - Class B Shares (Details) HTML 66K
147: R130 Equity - Share Capital - Movement in Outstanding HTML 67K
Shares (Details)
148: R131 Equity - Reserves - Legal Reserve (Details) HTML 73K
149: R132 Equity - Reserves - Unavailable Reserve (Details) HTML 62K
150: R133 Equity - Treasury Stock - Tabular Disclosure - HTML 72K
Shares (Details)
151: R134 Equity - Treasury Stock - Tabular Disclosure - HTML 74K
Value (Details)
152: R135 Equity - Treasury Stock - Additional Information HTML 71K
(Details)
153: R136 Equity - Distribution of Profit - Proposed HTML 61K
Distribution of Profit (Details)
154: R137 Equity - Distribution of Profit - Dividends Paid HTML 60K
(Details)
155: R138 Equity - Restricted Share Unit Retention Plan HTML 60K
(Details)
156: R139 Earnings Per Share - Calculation of basic earnings HTML 65K
per share (Details)
157: R140 Earnings Per Share - Weighted average number of HTML 64K
ordinary shares outstanding basic (Details)
158: R141 Earnings Per Share - Calculation of diluted HTML 66K
earnings per share (Details)
159: R142 Earnings Per Share - Weighted average number of HTML 67K
ordinary shares outstanding diluted (Details)
160: R143 Non-Controlling Interests - Movement (Details) HTML 134K
161: R144 Non-Controlling Interests - Summary of Financial HTML 139K
Information (Details)
162: R145 Non-Controlling Interests - Cash flows (Details) HTML 86K
163: R146 Non-Controlling Interests - Additional Information HTML 113K
(Details)
164: R147 Provisions - Summary (Details) HTML 71K
165: R148 Provisions - Movement in non-current and current HTML 69K
provisions (Details)
166: R149 Provisions - Net defined benefit liability of the HTML 70K
Biotest Group (Details)
167: R150 Provisions - Components of the costs for the HTML 93K
defined benefit plans (Details)
168: R151 Provisions - Reconciliation of the net present HTML 89K
value of the defined benefit obligation (Details)
169: R152 Provisions - Reconciliation of the fair value of HTML 83K
plan assets (Details)
170: R153 Provisions - Payments expected to be made in HTML 72K
subsequent years based on the current pension
obligations of the Biotest group (Details)
171: R154 Provisions - Plan assets of the group invested in HTML 71K
asset classes (Details)
172: R155 Provisions - Actuarial assumptions used in pension HTML 68K
plans calculation (Details)
173: R156 Provisions - Sensitivity analysis of actuarial HTML 79K
assumptions used in pension plans calculation
(Details)
174: R157 Provisions - Breakdown for expense for defined HTML 64K
contribution plans (Details)
175: R158 Financial Liabilities - Summary (Details) HTML 91K
176: R159 Financial Liabilities - Other (Details) HTML 91K
177: R160 Financial Liabilities - Movement in Senior Notes HTML 81K
(Details)
178: R161 Financial Liabilities - Promissory Notes (Details) HTML 72K
179: R162 Financial Liabilities - Loans and Borrowings HTML 159K
(Details)
180: R163 Financial Liabilities - Other current loans HTML 73K
(Details)
181: R164 Financial Liabilities - Senior Debt (Details) HTML 110K
182: R165 Financial Liabilities - Revolving credit facility HTML 77K
and other (Details)
183: R166 Financial Liabilities - Other Financial HTML 122K
Liabilities (Details)
184: R167 Financial Liabilities - Changes in liabilities HTML 99K
derived from financing activities (Details)
185: R168 Trade and Other Payables (Details) HTML 74K
186: R169 Other Current Liabilities (Details) HTML 69K
187: R170 Net Revenues - Distribution by Segment (Details) HTML 77K
188: R171 Net Revenues - Geographical Distribution (Details) HTML 72K
189: R172 Net Revenues - Discounts and Other Reductions HTML 74K
(Details)
190: R173 Net Revenues - Movement in Discounts and Other HTML 125K
Reductions (Details)
191: R174 Personnel Expenses (Details) HTML 87K
192: R175 Expenses by Nature - Amortization and Depreciation HTML 74K
(Details)
193: R176 Expenses by Nature - Other Operating Income and HTML 68K
Expenses (Details)
194: R177 Expenses by Nature - Other Operating Income and HTML 90K
Expenses, Components (Details)
195: R178 Finance Result (Details) HTML 92K
196: R179 Taxation - Reconciliation of accounting and HTML 87K
taxable income (Details)
197: R180 Taxation - Income tax expense - Total income tax HTML 67K
expense (Details)
198: R181 Taxation - Deferred tax assets and liabilities HTML 105K
(Details)
199: R182 Taxation - Movement in deferred tax assets and HTML 68K
liabilities (Details)
200: R183 Taxation - Deferred tax assets and liabilities, HTML 90K
others (Details)
201: R184 Other Commitments with Third Parties and Other HTML 147K
Contingent Liabilities (Details)
202: R185 Other Commitments with Third Parties and Other HTML 182K
Contingent Liabilities - Share-based payment plan
(Details)
203: R186 Other Commitments with Third Parties and Other HTML 72K
Contingent Liabilities - Purchase commitments
(Details)
204: R187 Financial Instruments - Classification by nature, HTML 163K
category and fair value (Details)
205: R188 Financial Instruments - Maximum level of exposure HTML 88K
to credit risk (Details)
206: R189 Financial Instruments - Credit Risk - Trade HTML 102K
receivables net of the bad debt provision by
ageing (Details)
207: R190 Financial Instruments - Trade Receivables - HTML 76K
Movement in the bad debt provision (Details)
208: R191 Financial Instruments - Liquidity risk (Details) HTML 67K
209: R192 Financial Instruments - Contractual Maturity Dates HTML 115K
of Financial Liabilities (Details)
210: R193 Financial Instruments - Currency Risk (Details) HTML 108K
211: R194 Financial Instruments - Interest Rate Risk HTML 78K
(Details)
212: R195 Financial Instruments - Financial derivatives HTML 138K
(Details)
213: R196 Financial Instruments - Financial derivatives - HTML 100K
Hedging derivative financial instruments (Details)
214: R197 Balances and Transactions with Related Parties HTML 162K
(Details)
215: R198 Subsequent events (Details) HTML 74K
216: R199 Subsequent events - Acquisition of 7 plasma HTML 77K
centers from ImmunoTek (Details)
217: R200 Subsequent events - Acquisition date fair value of HTML 83K
assets acquired and liabilities assumed (Details)
218: R201 Appendix I - Information on Group Companies, HTML 323K
Associates and others (Details)
219: R202 Appendix II - Operating Segments (Details) HTML 144K
220: R203 Appendix II - Reporting by Geographical Area HTML 85K
(Details)
221: R204 Appendix III - Changes in Other Intangible Assets HTML 128K
(Details)
222: R205 Appendix IV - Movement in Rights of Use (Details) HTML 121K
223: R206 Appendix V - Movement in Property, Plant and HTML 114K
Equipment (Details)
225: XML IDEA XML File -- Filing Summary XML 436K
228: XML XBRL Instance -- grfs-20231231x20f_htm XML 20.88M
224: EXCEL IDEA Workbook of Financial Report Info XLSX 644K
14: EX-101.CAL XBRL Calculations -- grfs-20231231_cal XML 506K
15: EX-101.DEF XBRL Definitions -- grfs-20231231_def XML 2.66M
16: EX-101.LAB XBRL Labels -- grfs-20231231_lab XML 4.48M
17: EX-101.PRE XBRL Presentations -- grfs-20231231_pre XML 3.77M
13: EX-101.SCH XBRL Schema -- grfs-20231231 XSD 888K
226: JSON XBRL Instance as JSON Data -- MetaLinks 995± 1.61M
227: ZIP XBRL Zipped Folder -- 0001104659-24-049471-xbrl Zip 2.31M
Exhibit 15.1
Date 19th April 2024
Securities and Exchange Commission
Washington, D.C. 20549
Ladies and Gentlemen:
We are currently principal accountants for Grifols, S.A. and subsidiaries (Grifols) and, under the date of April 19, 2024, we reported on the consolidated financial statements of Grifols as of and for the years ended December 31, 2023 and 2022, and the effectiveness of internal control over financial reporting as of December 31, 2023. On June 16, 2023, we were notified that Grifols engaged Deloitte, S.L. as its principal accountant for the year ending December 31, 2024 and that the auditor-client relationship with KPMG Auditores, S.L. will cease upon completion of the audit of Grifols’ consolidated financial statements as of and for the year ended December 31, 2023, and the effectiveness of internal control over financial reporting as of December 31, 2023, and the issuance of our reports thereon. We have read Grifols’s statements included under Item 16.F of its Form 20-F dated April 19, 2023, and we agree with such statements.
Very truly yours,
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/24 | ||||
| Filed on: | 4/19/24 | |||
| For Period end: | 12/31/23 | |||
| 6/16/23 | 6-K | |||
| 4/19/23 | ||||
| 12/31/22 | 20-F | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/18/23 Grifols SA 20-F 12/31/22 217:56M Toppan Merrill/FA 4/29/22 Grifols SA 20-F 12/31/21 212:54M Toppan Merrill/FA 4/09/21 Grifols SA 20-F 12/31/20 223:53M Toppan Merrill/FA 4/06/20 Grifols SA 20-F 12/31/19 221:55M Toppan Merrill/FA 4/23/19 Grifols SA 20-F/A 12/31/18 4:20M Toppan Merrill/FA 4/06/18 Grifols SA 20-F 12/31/17 202:42M Toppan Merrill/FA 7/12/12 Deutsche Bank Tr Co Americas/… Gp F-6EF 7/12/12 4:291K Grifols SA E-Data Systems, Inc./FA 3/09/11 Deutsche Bank Tr Co Americas/… Gp F-6 3:578K Grifols SA E-Data Systems, Inc./FA 5/18/09 Grifols SA F-6 3:592K E-Data Systems, Inc./FA |